Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 8/20 | 0.45 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1032169 | 0.93 | HIF1A (0.44) | HIF1AEPAS1RXFP1TRPV4 | |
| SCHEMBL1076689 | 0.88 | FGFR3 (0.47) | HIF1AEPAS1FGFR3WNT3ALMNA | |
| SCHEMBL1033836 | 0.86 | CNR2 (0.47) | HIF1AEPAS1THRBCNR2TRPV4 | |
| SCHEMBL1076860 | 0.86 | CNR2 (0.55) | THRBRXFP1CNR2TRPV4LMNA | |
| SCHEMBL13187591 | 0.84 | HIF1A (0.54) | HIF1AEPAS1THRBFGFR3CNR2 | |
| SCHEMBL1075405 | 0.84 | SCD (0.48) | THRBRXFP1CNR2TRPV4WNT3A | |
| SCHEMBL1033536 | 0.84 | ALK (0.51) | THRBCNR2TRPV4LMNA | |
| SCHEMBL12029266 | 0.82 | HIF1A (0.50) | HIF1AEPAS1THRBFGFR3RXFP1 | |
| SCHEMBL1033470 | 0.82 | MCHR1 (0.41) | HIF1AEPAS1FGFR3 | |
| SCHEMBL1030625 | 0.80 | BRAF (0.54) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| EP-2273992-B1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2011-02-24 | — | — | US | disclosed |
| EP-2273992-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009134973-A1 | QUENOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046110-A1 | QUINOLINES AND RELATED ANALOGS AS SIRTUIN MODULATORS | SIRT3, SIRT1, SIRT2 | HIF1A 866/4885EPAS1 520/4885THRB 1522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.